Considering the key role of IL-1 in tumor-promoting inflammation in PDAC, IL-1 inhibition by a recombinant IL-1R antagonist (IL-1RA) (anakinra, ANK) has been tested in in vitro and in vivo preclinical studies, demonstrating that ANK is an effective anti-tumor agent [23,34,35,36]. This evidence concerns the gene IL1A and neoplasm.